SpyGlass Pharma Raises $150 Million in Initial Public Offering

Published on February 9, 2026
ALISO VIEJO, Calif.—SpyGlass Pharma, Inc. (Nasdaq: SGP), a late-stage biopharmaceutical company focused on intraocular lens and drug delivery solutions for chronic eye conditions such as glaucoma, announced it raised $150 million in its initial public offering (IPO). The IPO priced 9,375,000 shares of common stock at $16 per share.
Continue reading on website
Other news

Johnson & Johnson Named Inaugural Global Impact Award Winner by the Healthcare Businesswomen's Association

February 9, 2026
FAIRFIELD, N.J.—Johnson & Johnson (NYSE: JNJ) has been named the inaugural recipient of the Global Impact Award by the Healthcare Businesswomen's Association (HBA), a global leadership accelerator, business growth partner, and enterprise solution for the health care and life sciences industries. The HBA's first-ever Global Impact Award recognizes organizations whose leadership practices, innovatio

American Optometric Association’s 2025 Advocacy Efforts Set the Stage for 2026, Group Says

February 9, 2026
ST. LOUIS—The American Optometric Association (AOA) announced that it achieved several significant federal and state advocacy achievements for doctors and patients in 2025, including securing a 2.5 percent increase in Medicare physician reimbursement for 2026, reversing a scheduled pay cut; a suite of tax benefits for optometry practices; and recognizing AOA as a physician-level certifying body fo